title: A systematic review on [(18)F]FLT-PET uptake as a measure of treatment response in cancer patients.
abstract: Imaging biomarkers have a potential to depict the hallmarks of cancers that characterise cancer cells as compared to normal cells. One pertinent example is 3'-deoxy-3'-(18)F-fluorothymidine positron emission tomography ([(18)F]FLT-PET), which allows non-invasive in vivo assessment of tumour proliferation. Most importantly, [(18)F]FLT does not seem to be accumulating in inflammatory processes, as seen in [(18)F]-fludeoxyglucose, the most commonly used PET tracer for assessment of cell metabolism. [(18)F]FLT could therefore provide additional information about the tumour biology before, during and after treatment. This systematic review focuses on the use of [(18)F]FLT-PET tumour uptake values as a measure of tumour response to therapeutic interventions. The clinical studies which evaluated the role of [(18)F]FLT-PET as a measure of tumour response to treatment are summarised and the evidence linking [(18)F]FLT-PET tumour uptake values with clinical outcome is evaluated.
authors.affiliation: European Organisation for Research and Treatment of Cancer (EORTC), Department of Translational research, Radiotherapy and Imaging (TRI), Brussels, Belgium.
authors.forename: V R
authors.initials: VR
authors.lastname: Bollineni
authors.affiliation: Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: ge.kramer@vumc.nl.
authors.forename: G M
authors.initials: GM
authors.lastname: Kramer
authors.affiliation: Medical Library, VU university Medical Center, Amsterdam, The Netherlands.
authors.forename: E P
authors.initials: EP
authors.lastname: Jansma
authors.affiliation: European Organisation for Research and Treatment of Cancer (EORTC), Department of Translational research, Radiotherapy and Imaging (TRI), Brussels, Belgium.
authors.forename: Y
authors.initials: Y
authors.lastname: Liu
authors.affiliation: The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, Department of Nuclear Medicine, London, United Kingdom.
authors.forename: W J G
authors.initials: WJ
authors.lastname: Oyen
mesh_terms: D049109:Cell Proliferation; D015224:Dideoxynucleosides / Q000493:pharmacokinetics*; D018572:Disease-Free Survival; D006801:Humans; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D016896:Treatment Outcome
chemical_list: D015224:Dideoxynucleosides; D019275:Radiopharmaceuticals; C002854:alovudine
keywords: 3′-Deoxy-3′-(18F)fluorothymidine; Alovudine; Cell proliferation; Chemoradiotherapy; Chemotherapy; Imaging biomarker; Neoplasms; Postitron-emission tomography; Radiotherapy